Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-11-28

FDA Approved: DEFEROXAMINE — Supplemental Application (Fresenius Kabi USA, LLC)

View source ↗

Summary

FDA approved a supplemental application for Deferoxamine (deferoxamine mesylate) submitted by Fresenius Kabi USA, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Deferoxamine (deferoxamine)

Snippet

SUPPL AP for DEFEROXAMINE (DEFEROXAMINE MESYLATE)